×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agendas
Session 9C: Clinically Relevant Specifications: Technical Considerations and Regulatory Expectations
Session Chair(s)
Nagesh Bandi, PhD
Executive Director
Merck & Co., Inc, United States
Speaker(s)
Novel Approaches to Better Understand Drug Product Design and Testing
Phil D Floyd, PhD
GlaxoSmithKline, United States
Head, Analyical Development
Strategies for Ensuring Dissolution and Clinical Performance
Vivek Purohit, PhD
Pfizer, Inc., US, United States
Director
Clinically Relevant Specifications: FDA Perspective
Angelica Dorantes, PhD, MSc
FDA, United States
Biopharmaceutics Branch Chief (acting), Office of Pharmaceutical Quality, CDER
Have an account?